Possible Link Between Spousal Depressed Mood, Cancer Survivor Quality of Life
the Cancer Therapy Advisor take:
Spousal depressed mood and poor health-related quality of life (HRQoL) may increase the risk of depressed mood and poor HRQoL in cancer survivors, especially female survivors, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
A longitudinal study investigated data from the 2004-2012 Medical Expenditures Panel Survey and another sample of cancer-free dyads.
The data involved reports of depressed mood, psychologic distress, and mental and physical health-related quality of life (HRQoL) from cancer survivors and their spouses (n = 910 dyads). The cancer survivors and their spouses reported these factors at two time points (T1/T2).
The impact of psychosocial factors at T1 on depressed mood at T2 was evaluated by dyadic multilevel models—sociodemographics, cancer type, survivor treatment status, and depressed mood at T1 were all controlled.
Results showed that cancer survivors with spouses who reported depressed mood at T1 were 4.27 times more likely to demonstrate depressed mood at the T2 report (95% CI: 2.01, 9.07].
When spouses reported a better mental and physical HRQoL at T1, there was a 30% decrease in cancer survivor depressed mood at T2.
The study suggests that evaluations should be conducted to see if the incorporation of spousal care into psychooncology and survivorship programs will help improve survivor outcomes.
Spousal depressed mood and poor health-related quality of life may increase risk of depressed mood in cancer survivors.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma